الفهرس 
AcknowledgmentOnly 14 pages are availabe for public view
 |  | from | 109 |  |  |
| | | from | 109 | | |
Abstract
Oral sildenafil has been shown to be effective in patients with pulmonary arterial hypertension.
Objective:
To assess the effect of oral sildenafil in patients with secondary pulmonary hypertension. Design: A three months non-controlled study. Setting: Fayioum university hospital from May 2009 to January 2011.
Patients and Methods:
Thirty patients with secondary pulmonary hypertension were receiving sildenafil, 25 mg daily, titrated to 50mg and 75 mg daily, as tolerated. Of 30 patients who received treatment, 28patients completed the study.
Change in hemodynamic measurements from baseline as detected by echocardiography (primary end point) and improvement in exercise capacity measured by (6-minute walk distance).
Results:
Significant increase in exercise tolerance as regard 6MWT (sex minutes walk test) which increased from 290.2±55.4 m to 406.9±72.9 m, p=0.001. There was significant reduction in PASP (pulmonary artery systolic pressure), PASP was (86.5±13.8) mmHg at baseline and decreased to (73.8±11.5) mmHg, p=0.001, with no significant effect on systemic blood pressure. There were also no significant changes regarding ventricular function or geometry. The effect of 50 and 75 mg of sildenafil were not significantly different.
Conclusion:
• Sildenafil therapy is well tolerated and appears to be safe in patients with secondary pulmonary hypertension.
• 2-Mid-term (three months) oral sildenafil therapy led to improved pulmonary haemodynamic regarding to reduction in pulmonary pressure and increase of exercise activities
• Sildenafil at 50 mg is enough for treatment of pulmonary hypertension.